Literature DB >> 10360713

Intervention based on monthly monitoring decreases hemodialysis access thrombosis.

J J Sands1, P A Jabyac, C L Miranda, B J Kapsick.   

Abstract

We randomized 103 patients (68 arteriovenous [AV] fistulas, 35 polytetrafluoroethylene [PTFE] grafts; mean follow-up 197 days) to monthly measurement of access flow (QAT), monthly measurement of static venous pressure (VPS), or no monthly monitoring (control patients) to determine whether access thrombosis would decrease. Patients with access flow <750 cc/min or with static venous pressure > or =0.5 were referred for angiography and angioplasty of stenotic lesions > or =50%. Six of sixty-two (9.7%) of monthly monitored patients (MM) developed access thrombosis vs. 9 of 41 (22%) of control patients (p<0.05). Fewer MM patients developed thrombosis in AV fistulas (2.4% [2 of 42] vs. 15.4% [4 of 26] control patients; p<0.05). Monthly monitored patients had fewer thrombotic episodes than control patients (19 vs. 125 per 100 patient-years; p<0.01). Thrombosis rates were lowest in patients receiving monthly access flow measurement (5.9 [QAT] vs. 30.3 per 100 patient-years [VPS]; p<0.05). In conclusion, intervention based on monthly access flow measurement or static venous pressure decreased hemodialysis access thrombosis. Measurement of access flow tended to result in lower thrombosis rates than after static venous pressure. We believe that monthly access flow measurement will ensure the lowest incidence of thrombosis and decrease the cost of access maintenance.

Entities:  

Mesh:

Year:  1999        PMID: 10360713     DOI: 10.1097/00002480-199905000-00008

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  14 in total

1.  Patency and life-spans of failing hemodialysis grafts in patients undergoing repeated percutaneous de-clotting.

Authors:  A V Mansilla; B D Toombs; W K Vaughn; J I Zeledon
Journal:  Tex Heart Inst J       Date:  2001

Review 2.  A meta-analysis of randomized clinical trials assessing hemodialysis access thrombosis based on access flow monitoring: where do we stand?

Authors:  Timothy Muchayi; Loay Salman; Leonardo J Tamariz; Arif Asif; Abid Rizvi; Oliver Lenz; Roberto I Vazquez-Padron; Marwan Tabbara; Gabriel Contreras
Journal:  Semin Dial       Date:  2015-01-28       Impact factor: 3.455

3.  Optimizing function and treatment of hemodialysis grafts and fistulae.

Authors:  Thomas M Vesely
Journal:  Semin Intervent Radiol       Date:  2004-06       Impact factor: 1.513

4.  How is arteriovenous fistula longevity best prolonged?: The role of surveillance.

Authors:  Loay H Salman
Journal:  Semin Dial       Date:  2014-09-18       Impact factor: 3.455

5.  Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting postprocedural fistula patency.

Authors:  Ayse Aktas; Alper Bozkurt; Bulent Aktas; Ismail Kirbas
Journal:  Diagn Interv Radiol       Date:  2015 Mar-Apr       Impact factor: 2.630

6.  Surveillance of hemodialysis vascular access.

Authors:  William L Whittier
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

7.  The Effect of Risk of Maturation Failure and Access Type on Arteriovenous Access-Related Costs among Hemodialysis Patients.

Authors:  Sarah D Kosa; Amiram Gafni; Lehana Thabane; Charmaine E Lok
Journal:  Kidney360       Date:  2020-03-13

Review 8.  Pre-emptive correction for haemodialysis arteriovenous access stenosis.

Authors:  Pietro Ravani; Robert R Quinn; Matthew J Oliver; Divya J Karsanji; Matthew T James; Jennifer M MacRae; Suetonia C Palmer; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2016-01-07

9.  Surveillance and monitoring of dialysis access.

Authors:  Lalathaksha Kumbar; Jariatul Karim; Anatole Besarab
Journal:  Int J Nephrol       Date:  2011-11-22

10.  Does regular surveillance improve the long-term survival of arteriovenous fistulas?

Authors:  Ashwin Shetty; William L Whittier
Journal:  Int J Nephrol       Date:  2011-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.